Developer docs
API playgroundTry for free, no card

Search company profiles

Xact Laboratories

Full company profile

uuid000h3za

Namestring
Xact Laboratories
Legal namestring
Xact Laboratories, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Xact Laboratories, LLC is a privately held, CLIA-certified pharmacogenomic (PGx) testing company founded in 2012 and headquartered in Twinsburg, Ohio. The company operates two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management, and metabolic therapeutic areas using next-generation sequencing and real-time PCR; and XVIS (Xact Vertical Integration System), a patent-pending interoperability platform that delivers PGx insights natively into Epic, Cerner, HL7 FHIR-compliant systems, pharmacy benefit managers, retail pharmacy systems, and payer claims platforms via RESTful APIs and webhooks. The platform combines an automated prior authorization clearinghouse with rules-based prescription interception logic that flags genetically ineffective medications before they are dispensed, with company-disclosed outcomes of 95% accuracy in predicting drug response, 40-45% reduction in adverse drug reactions, and $2.3M average annual savings per health system.

The business model spans three revenue streams: per-test pharmacogenomic testing services (one-time license model on enterprise contracts), non-exclusive technology licensing of the patented integration and prior authorization IP to healthcare technology buyers, and recurring evidence-based prescribing services sold on multi-year contracts to payers, PBMs, and self-insured employers on a value/outcomes basis. The company sells primarily through an enterprise field sales motion targeting health insurance payers, PBMs, hospital systems, and self-insured employer groups, supplemented by industry-conference presence (NCPDP Annual Technology & Business Conference), PR Newswire distribution for patent and award announcements, and inbound enterprise demo requests through the website. Pricing is quote-based with no publicly disclosed price points, and no named enterprise customers, revenue figures, or institutional funding rounds appear in available data. The intellectual property position is unusually broad for an 11-50 employee company, with 8 issued US patents and 5 pending applications accumulated between 2022 and 2026 covering formulary overlays, automated prior authorization, real-time genetic data transmission, and pharmacy fill-blocking.

Short descriptiontext

Xact Laboratories is a CLIA-certified pharmacogenomic testing company that combines the XactMed4U genetic test panel with the XVIS integration platform to deliver PGx insights, automated prior authorization, and prescription interception into EHR, PBM, payer, and pharmacy workflows for enterprise healthcare buyers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTwinsburg, United States
HQ citystring
Twinsburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenomic testing services, precision medicine diagnostics, automated prior authorization, EHR clinical decision support, pharmacy benefit integration
Industry3 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAEAKAL
PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Pharmacogenomic Testing and Precision Medicine Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmacogenomic Testing Services
TypeOne Time License
Description

Revenue generated from providing comprehensive pharmacogenomic testing panels (XactMed4U and XVIS products) to healthcare providers, payers, PBMs, and health systems. Testing covers 200+ medications and 15+ gene variants with real-time results delivered via EHR integration.

xactlaboratories.com
2Technology Licensing
TypeLicensing Royalties
Description

Non-exclusive licensing opportunities offered to organizations looking to integrate clinical PGx workflows. Patent-protected technology available for licensing to healthcare technology companies, payers, and pharmacy systems.

3Evidence-Based Prescribing Services
TypeSubscription Recurring
Description

Services targeted at payers, PBMs, health systems, and self-insured employer groups providing value-based outcomes including improved STAR and HEDIS ratings, reduced total medical spend, and improved medication adherence.

xactlaboratories.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based and varies by customer segment (payers, PBMs, health systems, self-insured employers). Contact team via website for demo and pricing information.

xactlaboratories.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1XactMed4U
Description

Comprehensive pharmacogenomic testing platform covering multiple therapeutic areas for personalized medicine, featuring automated prior authorization and AI-enhanced prescription decision support.

xactlaboratories.com
+1 more record
Core offering1 text field

Xact Laboratories operates a CLIA-certified laboratory and software platform that delivers comprehensive pharmacogenomic (PGx) testing covering 200+ medications and 15+ gene variants. Its XactMed4U testing panel combines a patient-friendly cheek swab with AI-enhanced prescription decision support, while its patent-pending XVIS integration system pushes genetic insights in real time into Epic, Cerner, PBM, payer and health information exchange systems. The company's proprietary automated prior authorization clearinghouse intercepts potentially harmful or ineffective prescriptions before dispensing and suggests formulary-aligned alternatives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 95% accuracy rate in predicting drug response based on genetic markers
+8 more records
Product overview1 text field

Xact Laboratories offers a unified pharmacogenomic testing platform comprising two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants using next-generation sequencing and real-time PCR analysis; and XVIS, a patent-protected vertical integration system that delivers clinically actionable PGx insights across all major healthcare platforms including Epic, Cerner, HL7 FHIR, pharmacy benefit managers, and payer systems. The platform combines automated prior authorization clearinghouse technology with AI-enhanced prescription decision support to intercept potentially harmful medications before dispensing, achieving 95% accuracy in predicting drug response and 40% reduction in adverse drug reactions. Services are delivered through seamless EHR integration with real-time clinical decision support within provider native workflows.

Product and service3 records
1XactMed4U
CategoryPharmacogenomic testing
Description

Comprehensive pharmacogenomic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management and metabolic therapeutic areas. Combines a patient-friendly cheek swab with patented automated prior authorization technology and AI-enhanced prescription decision support to deliver precision medicine at the point of care. Targets healthcare providers, payers, PBMs and self-insured employer groups.

2XVIS (Xact Vertical Integration System)
CategoryHealthcare integration and clinical decision support software
Description

Patent-pending interoperability platform that delivers clinically actionable pharmacogenomic insights within provider's native and familiar workflow. Seamlessly integrates with every major healthcare platform—payers, PBMs, pharmacy systems, HIEs and EHR systems (Epic, Cerner)—through RESTful APIs, webhooks and HL7 FHIR-compliant data exchange. Provides contextual clinical decision support, automated prior authorization, claims processing integration and formulary optimization in real time.

3PGx Testing Services
CategoryLaboratory testing and pharmacogenomic services
Description

Evidence-based prescribing services delivered through the CLIA-certified Xact Laboratories laboratory, including pharmacogenomic testing with automated medication safety checks prior to pickup, outcomes optimization for payers/PBMs/health systems/self-insured employers, and convenient testing at the pharmacy counter. Targets enterprise healthcare buyers seeking improved STAR/HEDIS ratings, reduced total medical spend, and improved medication adherence.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OneOme provides a RightMed PGx test and decision-support platform with EHR integration, directly competing with XactMed4U and XVIS for payer and health system contracts in personalized prescribing.

2Sema4
TypeEmerging player
Description

Sema4 (now part of GeneDx) offers genomic and pharmacogenomic testing with health system integration, competing with Xact in advanced clinical decision support for personalized prescribing.

TypeDirect peer
Description

Coriell Life Sciences offers enterprise PGx services with pharmacogenomic interpretation and decision-support tools, serving payers, PBMs, and health systems in direct competition with Xact.

TypeDirect peer
Description

Genomind offers the GeneSight PGx test, the most established direct competitor in pharmacogenomic decision support, with similar focus on mental health medications and integration into prescriber workflows.

TypeBroad incumbent
Description

Mayo Clinic Laboratories is a major reference laboratory offering PGx panels alongside broad diagnostic services, competing with Xact's CLIA-certified lab for hospital and health system volume.

TypeDirect peer
Description

Myriad Genetics operates GeneSight (acquired via Myriad Neuroscience) and broader PGx offerings, making it a large, well-capitalized competitor with established payer contracts in the same therapy-selection niche.

TypeBroad incumbent
Description

Invitae is a large-scale clinical genetic testing company with broader hereditary disease focus but overlapping pharmacogenomic and therapy-selection capabilities aimed at health systems.

TypeBroad incumbent
Description

Quest Diagnostics is a national reference lab offering pharmacogenomic and clinical decision support through its Cardio IQ and PGx panels, with substantially larger scale and payer reach than Xact.

9Genelex
TypeDirect peer
Description

Genelex provides YouScript, a PGx testing and clinical decision support platform for clinicians, with comparable focus on integrating genetic insights into prescribing workflows.

TypeEmerging player
Description

Color Health provides population-scale genetic testing with employer and health system channels; while broader than pure PGx, it overlaps with Xact in employer-sponsored pharmacogenomic and preventive programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xact Laboratories

Pharmacogenomic Testing and Precision Medicine Diagnosticsxactlaboratories.com

Xact Laboratories is a CLIA-certified pharmacogenomic testing company that combines the XactMed4U genetic test panel with the XVIS integration platform to deliver PGx insights, automated prior authorization, and prescription interception into EHR, PBM, payer, and pharmacy workflows for enterprise healthcare buyers.

What Xact Laboratories does

Xact Laboratories, LLC is a privately held, CLIA-certified pharmacogenomic (PGx) testing company founded in 2012 and headquartered in Twinsburg, Ohio. The company operates two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management, and metabolic therapeutic areas using next-generation sequencing and real-time PCR; and XVIS (Xact Vertical Integration System), a patent-pending interoperability platform that delivers PGx insights natively into Epic, Cerner, HL7 FHIR-compliant systems, pharmacy benefit managers, retail pharmacy systems, and payer claims platforms via RESTful APIs and webhooks. The platform combines an automated prior authorization clearinghouse with rules-based prescription interception logic that flags genetically ineffective medications before they are dispensed, with company-disclosed outcomes of 95% accuracy in predicting drug response, 40-45% reduction in adverse drug reactions, and $2.3M average annual savings per health system.

The business model spans three revenue streams: per-test pharmacogenomic testing services (one-time license model on enterprise contracts), non-exclusive technology licensing of the patented integration and prior authorization IP to healthcare technology buyers, and recurring evidence-based prescribing services sold on multi-year contracts to payers, PBMs, and self-insured employers on a value/outcomes basis. The company sells primarily through an enterprise field sales motion targeting health insurance payers, PBMs, hospital systems, and self-insured employer groups, supplemented by industry-conference presence (NCPDP Annual Technology & Business Conference), PR Newswire distribution for patent and award announcements, and inbound enterprise demo requests through the website. Pricing is quote-based with no publicly disclosed price points, and no named enterprise customers, revenue figures, or institutional funding rounds appear in available data. The intellectual property position is unusually broad for an 11-50 employee company, with 8 issued US patents and 5 pending applications accumulated between 2022 and 2026 covering formulary overlays, automated prior authorization, real-time genetic data transmission, and pharmacy fill-blocking.

Xact Laboratories firmographics

Firmographics
Name
Xact Laboratories
Legal name
Xact Laboratories, LLC
Website
https://xactlaboratories.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Xact Laboratories is a CLIA-certified pharmacogenomic testing company that combines the XactMed4U genetic test panel with the XVIS integration platform to deliver PGx insights, automated prior authorization, and prescription interception into EHR, PBM, payer, and pharmacy workflows for enterprise healthcare buyers.
Ownership category
akta.pro rank

Xact Laboratories industry classification

Industry
Product category
Pharmacogenomic Testing and Precision Medicine Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAEAKAL
PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools)

Keywords

  • Pharmacogenomic testing services
  • Precision medicine diagnostics
  • Automated prior authorization
  • EHR clinical decision support
  • Pharmacy benefit integration

Where Xact Laboratories is headquartered

Location

Headquarters

HQ city
Twinsburg
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Xact Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Pharmacogenomic Testing Services: Revenue generated from providing comprehensive pharmacogenomic testing panels (XactMed4U and XVIS products) to healthcare providers, payers, PBMs, and health systems. Testing covers 200+ medications and 15+ gene variants with real-time results delivered via EHR integration.
  2. Technology Licensing: Non-exclusive licensing opportunities offered to organizations looking to integrate clinical PGx workflows. Patent-protected technology available for licensing to healthcare technology companies, payers, and pharmacy systems.
  3. Evidence-Based Prescribing Services: Services targeted at payers, PBMs, health systems, and self-insured employer groups providing value-based outcomes including improved STAR and HEDIS ratings, reduced total medical spend, and improved medication adherence.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Xact Laboratories product offering

Product offering

Core offering

Xact Laboratories operates a CLIA-certified laboratory and software platform that delivers comprehensive pharmacogenomic (PGx) testing covering 200+ medications and 15+ gene variants. Its XactMed4U testing panel combines a patient-friendly cheek swab with AI-enhanced prescription decision support, while its patent-pending XVIS integration system pushes genetic insights in real time into Epic, Cerner, PBM, payer and health information exchange systems. The company's proprietary automated prior authorization clearinghouse intercepts potentially harmful or ineffective prescriptions before dispensing and suggests formulary-aligned alternatives.

Product overview

Xact Laboratories offers a unified pharmacogenomic testing platform comprising two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants using next-generation sequencing and real-time PCR analysis; and XVIS, a patent-protected vertical integration system that delivers clinically actionable PGx insights across all major healthcare platforms including Epic, Cerner, HL7 FHIR, pharmacy benefit managers, and payer systems. The platform combines automated prior authorization clearinghouse technology with AI-enhanced prescription decision support to intercept potentially harmful medications before dispensing, achieving 95% accuracy in predicting drug response and 40% reduction in adverse drug reactions. Services are delivered through seamless EHR integration with real-time clinical decision support within provider native workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • XactMed4U: Comprehensive pharmacogenomic testing platform covering multiple therapeutic areas for personalized medicine, featuring automated prior authorization and AI-enhanced prescription decision support.
  • XVIS

Products and services

  • XactMed4U Comprehensive pharmacogenomic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management and metabolic therapeutic areas. Combines a patient-friendly cheek swab with patented automated prior authorization technology and AI-enhanced prescription decision support to deliver precision medicine at the point of care. Targets healthcare providers, payers, PBMs and self-insured employer groups.
  • XVIS (Xact Vertical Integration System) Patent-pending interoperability platform that delivers clinically actionable pharmacogenomic insights within provider's native and familiar workflow. Seamlessly integrates with every major healthcare platform—payers, PBMs, pharmacy systems, HIEs and EHR systems (Epic, Cerner)—through RESTful APIs, webhooks and HL7 FHIR-compliant data exchange. Provides contextual clinical decision support, automated prior authorization, claims processing integration and formulary optimization in real time.
  • PGx Testing Services Evidence-based prescribing services delivered through the CLIA-certified Xact Laboratories laboratory, including pharmacogenomic testing with automated medication safety checks prior to pickup, outcomes optimization for payers/PBMs/health systems/self-insured employers, and convenient testing at the pharmacy counter. Targets enterprise healthcare buyers seeking improved STAR/HEDIS ratings, reduced total medical spend, and improved medication adherence.

Quantifiable outcome

  • 95% accuracy rate in predicting drug response based on genetic markers
  • +8 more outcomes

Companies that use Xact Laboratories

Customer profile

Segments5 records

Ideal customer profiles4 records

Xact Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability5 records

Feature4 records

Xact Laboratories partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Xact Laboratories competitors and assessment

Company assessment

Direct peers

  • OneOme: OneOme provides a RightMed PGx test and decision-support platform with EHR integration, directly competing with XactMed4U and XVIS for payer and health system contracts in personalized prescribing.
  • Coriell Life Sciences: Coriell Life Sciences offers enterprise PGx services with pharmacogenomic interpretation and decision-support tools, serving payers, PBMs, and health systems in direct competition with Xact.
  • Genomind: Genomind offers the GeneSight PGx test, the most established direct competitor in pharmacogenomic decision support, with similar focus on mental health medications and integration into prescriber workflows.
  • Myriad Genetics: Myriad Genetics operates GeneSight (acquired via Myriad Neuroscience) and broader PGx offerings, making it a large, well-capitalized competitor with established payer contracts in the same therapy-selection niche.
  • Genelex: Genelex provides YouScript, a PGx testing and clinical decision support platform for clinicians, with comparable focus on integrating genetic insights into prescribing workflows.

Emerging players

  • Sema4: Sema4 (now part of GeneDx) offers genomic and pharmacogenomic testing with health system integration, competing with Xact in advanced clinical decision support for personalized prescribing.
  • Color Health: Color Health provides population-scale genetic testing with employer and health system channels; while broader than pure PGx, it overlaps with Xact in employer-sponsored pharmacogenomic and preventive programs.

Broad incumbents

  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major reference laboratory offering PGx panels alongside broad diagnostic services, competing with Xact's CLIA-certified lab for hospital and health system volume.
  • Invitae: Invitae is a large-scale clinical genetic testing company with broader hereditary disease focus but overlapping pharmacogenomic and therapy-selection capabilities aimed at health systems.
  • Quest Diagnostics: Quest Diagnostics is a national reference lab offering pharmacogenomic and clinical decision support through its Cardio IQ and PGx panels, with substantially larger scale and payer reach than Xact.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Xact Laboratories compliance and trust

Trust signal

Compliance2 records

Xact Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xact Laboratories leadership team

Management profile

Number of profiles

Profiles5 records

Xact Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xact Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xact Laboratories

What does Xact Laboratories do?

Xact Laboratories operates a CLIA-certified laboratory and software platform that delivers comprehensive pharmacogenomic (PGx) testing covering 200+ medications and 15+ gene variants. Its XactMed4U testing panel combines a patient-friendly cheek swab with AI-enhanced prescription decision support, while its patent-pending XVIS integration system pushes genetic insights in real time into Epic, Cerner, PBM, payer and health information exchange systems. The company's proprietary automated prior authorization clearinghouse intercepts potentially harmful or ineffective prescriptions before dispensing and suggests formulary-aligned alternatives.

Is Xact Laboratories a public or private company?

Xact Laboratories is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Xact Laboratories founded?

Xact Laboratories was founded in 2012. It employs 1 to 10 people.

Where is Xact Laboratories based?

Xact Laboratories is headquartered in Twinsburg, United States, in the North America region.

How does Xact Laboratories make money?

Three revenue lines are on record. Pharmacogenomic Testing Services are the primary driver. The others are technology Licensing and evidence-Based Prescribing Services.

Who are Xact Laboratories's main competitors?

Direct peers on record are OneOme, Coriell Life Sciences, Genomind, Myriad Genetics and Genelex. Emerging players are Sema4 and Color Health. Broad incumbents are Mayo Clinic Laboratories, Invitae and Quest Diagnostics.

Does Xact Laboratories have an API?

Yes. RESTful APIs and webhooks for real-time data exchange with any healthcare platform. The API enables seamless integration with payer systems, pharmacy benefit managers, health information exchanges, and health systems including claims processing, prior authorization automation, formulary optimization, and clinical decision support. Developer documentation is at portal.pathxlis.com/Account/LogOn?ReturnUrl=%2f.

What industry is Xact Laboratories in?

Xact Laboratories's product category is Pharmacogenomic Testing and Precision Medicine Diagnostics. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePatent 12,640,242 Fuels Xact Labs' Genetic Data IntegrationThe U.S. Patent and Trademark Office issued U.S. Patent No. 12,640,242 to Xact Laboratories on May 26, 2026, granting federal intellectual property protection for the company's proprietary technology enabling real-time integration of genetic data into clinical and pharmacy systems. The patent, the company's eighth, is designed to help identify medication efficacy, dosage adjustments, and adverse reaction risks based on a patient's genetic profile. The company says this validation strengthens its credibility and creates future opportunities for commercialization, licensing, and strategic partnerships within the precision medicine landscape.PR NewswireNCPDP Foundation Announces Xact Laboratories as 2026 Honoree of the Prestigious Charles Pulido, R.Ph. Excellence AwardThe NCPDP Foundation presented the Charles Pulido, R.Ph. Excellence Award to Xact Laboratories during the President & CEO Leadership Appreciation Dinner on May 3, 2026, at NCPDP's Annual Technology & Business Conference. Xact Laboratories was honored for completing NCPDP Foundation-funded research on integrating pharmacogenomic data into pharmacist workflows, with the study finding that 95% of patients had PGx-identified medication problems, 59% of prescribers agreed to modify prescribing based on results, and 87% of patient consultations were completed. The annual award recognizes one grantee who demonstrates commitment to collaboration, innovation, and excellence in healthcare.PR NewswireXact Laboratories Announces Strategic Partnership with a national Switch to provide integrated PGx results at the point of prescription fulfillmentXact Laboratories announced a strategic partnership with a national prescription claims clearinghouse (Switch) to integrate pharmacogenomic test results directly into the prescription fulfillment workflow. The collaboration marks the first time evidence-based prescription medication management is integrated at the Switch level, enabling pharmacists and providers to receive real-time clinical alerts for medication adjustments based on PGx findings. Xact Laboratories is the only company capable of embedding PGx results into the pharmacy adjudication process, allowing automated medication guidance without patients carrying physical test reports.GlobeNewswireThe Good Clinic Expands Services with Pharmacogenetic Testing by Xact LaboratoriesThe Good Clinic is adding pharmacogenomic testing through Xact Laboratories to help clinicians tailor medications to individual genetics. The service aims to improve outcomes and reduce costs, as studies show 38-75% of patients show no response to initial drug treatment. The clinic plans to offer the service at all its locations.